Breaking News

Which doctors are most likely to use telehealth?

September 5, 2024
Health Tech Correspondent

Good morning health tech readers!

It's September, and that means back to business, beginning with my colleagues' startling new investigation about race in algorithms. Plus: a new slice of Medicare telehealth data.

Reach me: mario.aguilar@statnews.com

Investigation

The quest to remove race from a kidney disease calculator

In a new story, STAT's Usha Lee McFarling and Katie Palmer detail the contentious battle to remove race from a clinical calculator that helps assess the severity of kidney disease. Until recently, estimates of kidney function relied on flawed science to give different numbers to Black patients than others, underplaying life-threatening disease. Thanks to the hard work of researchers and probing questions from patients who wondered why assessments should consider race, the standard practice at most clinics has changed in just a few short years. But not before a few bruising battles that pitted a new generation of physicians with a more nuanced understanding of race against an earlier generation of doctors who were confident in the tools they'd used for decades.

The new story is the latest installment in Embedded Bias, a series where Usha and Katie's explore the use of race in clinical algorithms used in medicine and why it's so hard to take race out of the equation.

Read the latest story here


medical devices

Abbott's latest heart clip data doesn't resolve debate

It was meant as a tie-breaker, but after an Abbott heart clip showed divergent results in two trials, another study doesn't quite resolve the issue. The device, called MitraClip, is implanted to treat mitral regurgitation, a condition where blood leaks backward into the left heart chamber. It was approved by the Food and Drug Administration in 2019.

In newly presented data, people with the device were hospitalized for heart failure less than a control group and scored better on a quality of life measure. But as STAT's Lizzy Lawrence reports, without a reduction in mortality, the results paint a hazy picture of the device's value. Experts said that more research is needed to better understand who benefits the most from the treatment, especially since patients in the most recent trial were less sick than those in previous studies.

Read Lizzy's analysis here


Telehealth

A new angle on which docs use telehealth the most

As Medicare telehealth flexibilities rapidly approach their expiration date, researchers from Cornell examined 2022 Medicare fee-for-service claims to understand how physician characteristics impacted telehealth use. They focused on evaluation and management visits, because those lend themselves the most to telehealth compared to visits where there's a procedure.

The researchers billboard the fact that overall, female physicians were "significantly more likely" than male physicians to to deliver telehealth visits. They note the reasons for this warrant more research, but also hazard a guess at an explanation: "It is possible that female physicians, who tend to have greater familial responsibilities, place a higher value on the potential of scheduling and location flexibilities afforded by telehealth." A reach without evidence? Maybe! But to me it is a good reminder that when we talk about utilization numbers for telehealth, we ought to consider not only how technology enables more people to receive care — but also how it potentially eases the burden on physicians who deliver care.



Telehealth

The uncertain future of Hims' weight loss boom

Hims & Hers Health has stood up a thriving business around the shortage of wildly popular weightloss drugs like Wegovy and Zepbound. Under FDA rules, drugs subject to shortages can be manufactured by compounding pharmacies unaffiliated with drugmakers, and Hims, along with a litany of other online providers, have leaned in, offering GLP-1s to patients who are lining up in droves to get them.

Hims appears to plan to keep offering compounded versions of the drugs even after the shortages officially end, by taking advantage of a loophole that allows clinicians to prescribe versions of a drug that better meet the needs of a patient. For example, a child who can't swallow pills might require a liquid version of a drug. But it's unclear that a person would  benefit from a personalized dose of semaglutide.

Eli Lilly and Novo Nordisk, the companies that market the drugs, obviously aren't happy about this, and experts told STAT's Katie Palmer and Nicholas Florko that the strategy could land Hims in court. 

Read more here 


digital therapeutics

A fundraise, a clearance, and top-line data

  • Curio Digital Therapeutics, which earlier this year received FDA clearance for a digital treatment for postpartum depression, has raised $10 million. The company's founder and CEO Shailja Dixit told STAT that Curio will soon announce insurance coverage for its PPD product. It now plans to develop products around fertility and menopause. Investors include RYSE Asset Management, ONCE, a venture capital arm of Otsuka, Bridge Point Capital, and Avestria.
  • Big Health announced that the FDA cleared DaylightRx a prescription version of is app that helps people manage anxiety. Unlike the non-prescription version, available through employers and health plans, the prescription version can be ordered by clinicians for patients under their care. Big Health in August received clearance for SleepioRx, a prescription version of its app for people with insomnia.
  • Click Therapeutics announced positive data in a pivotal trial for CT-132, its digital treatment for migraines. The results have not yet been peer reviewed or evaluated by FDA.

More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • The Snoo can't help the people who need it most, STAT
  • Dialysis may prolong life for older patients. But not by much, New York Times
  • Recursion presents mixed data on lead AI-derived drug candidate, STAT

Thanks for reading! More on Tuesday - Mario

Mario Aguilar covers how technology is transforming health care. He is based in New York.


Enjoying STAT Health Tech? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments